CRISPR TherapeuticsCRISPR Therapeutics
CT

CRISPR Therapeutics

Biotechnology company developing transformative gene-based medicines using CRISPR/Cas9 gene editing technology.

2013Active

About

CRISPR Therapeutics is a Swiss-American biotechnology company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines for serious diseases. They develop cures for genetic diseases by precisely modifying DNA, with a diverse portfolio including treatments for hemoglobinopathies, oncology, and regenerative medicine. Their lead program, exagamglogene autotemcel (exa-cel), has received regulatory approval in several countries for sickle cell disease and transfusion-dependent beta thalassemia.

Technology stack

detected 2026-06-16
Est. monthly stack spend~$190/mo
EmailProofpoint
gateway-fronted
Hosting
self_managed
Stack
jQuery
Analytics
Google Analytics 4
Video
Vimeo
Cookie consent
OneTrust
Comments

No comments yet. Be the first to share your take.

Frequently asked

What does CRISPR Therapeutics do?

CRISPR Therapeutics is a Swiss-American biotechnology company focused on translating CRISPR/Cas9 gene-editing technology into transformative medicines for serious diseases. They develop cures for genetic diseases by precisely modifying DNA, with a diverse portfolio including treatments for hemoglobinopathies, oncology, and regenerative medicine. Their lead program, exagamglogene autotemcel (exa-cel), has received regulatory approval in several countries for sickle cell disease and transfusion-de…

How much funding has CRISPR Therapeutics raised?

CRISPR Therapeutics has raised a total of $547M in funding. The most recent round on record is Series B.

Where is CRISPR Therapeutics headquartered?

CRISPR Therapeutics is headquartered in Zug, Switzerland.

When was CRISPR Therapeutics founded?

CRISPR Therapeutics was founded in 2013.

What industry does CRISPR Therapeutics operate in?

CRISPR Therapeutics operates in Biotechnology, Gene Editing, Therapeutics, Pharmaceuticals.